ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
68 announcements
Zydus Lifesciences incorporated a new wholly owned subsidiary, Zara Merger SUB Inc., in the United States on April 24, 2026. The entity is part of an internal group restructuring within the pharmaceutical industry. The subsidiary has not yet commenced business operations and currently reports nil turnover.
Zydus Lifesciences received DCGI approval to initiate Phase III clinical trials for Zintrodiazine, a novel anti-malarial candidate. Two trials involving 651 and 390 patients will evaluate efficacy against P. falciparum and P. vivax malaria in India. This marks a significant milestone in developing alternatives to current artemisinin-based therapies facing resistance.
Zydus Lifesciences Limited received the Establishment Inspection Report (EIR) and approval from the USFDA for its oncology injectable facility in SEZ1, Ahmedabad. The approval follows a Pre-Approval Inspection conducted in November 2025 for a new isolator injectable line. This regulatory milestone clears the path for commercial manufacturing at the site.
Zydus Lifesciences' subsidiary, GRPPL, received an appellate order dropping a previously imposed GST penalty of ₹0.17 Crore (Rs. 1.66 million) for FY 2018-19. The Office of Commissioner (Appeals) Ahmedabad set aside the demand, resulting in no material impact on the company's financials or operations.
Zydus Lifesciences Limited has been assigned an overall ESG rating of 68 by ESGRAIL, an improvement from last year's 66. The rating was prepared independently based on publicly available information. This update reflects the company's ongoing commitment to environmental, social, and governance standards.
Zydus Lifesciences received final USFDA approval for Dapagliflozin Tablets (5 mg and 10 mg), used for type 2 diabetes. The drug had annual US sales of approximately ₹94,860 Crore. Zydus is eligible for 180 days of shared generic exclusivity, with manufacturing based in Ahmedabad SEZ.
Zydus Lifesciences received a favorable order from the GST Adjudication Authority, Gandhinagar, dropping a tax demand of ₹4.18 Crore for FY 2019-20. The company noted the event is not material under SEBI regulations and was disclosed as a good governance practice.
Zydus Lifesciences Limited received a favourable order from the GST Adjudication Authority in Gandhinagar. The order dropped a GST demand of ₹4.18 Crore (Rs. 41.77 million) for the financial year 2019-20. This positive regulatory outcome reduces the company's potential tax liabilities.